The impact of demographic, clinical, genetic, and imaging variables on tau PET status
PURPOSE: A substantial proportion of amyloid-β (Aβ)+ patients with clinically diagnosed Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI) are tau PET-negative, while some clinically diagnosed non-AD neurodegenerative disorder (non-AD) patients or cognitively unimpaired (CU) subjects are tau PET-positive. We investigated which demographic, clinical, genetic, and imaging variables contributed to tau PET status.
METHODS: We included 2338 participants (430 Aβ+ AD dementia, 381 Aβ+ MCI, 370 non-AD, and 1157 CU) who underwent [18F]flortaucipir (n = 1944) or [18F]RO948 (n = 719) PET. Tau PET positivity was determined in the entorhinal cortex, temporal meta-ROI, and Braak V-VI regions using previously established cutoffs. We performed bivariate binary logistic regression models with tau PET status (positive/negative) as dependent variable and age, sex, APOEε4, Aβ status (only in CU and non-AD analyses), MMSE, global white matter hyperintensities (WMH), and AD-signature cortical thickness as predictors. Additionally, we performed multivariable binary logistic regression models to account for all other predictors in the same model.
RESULTS: Tau PET positivity in the temporal meta-ROI was 88.6% for AD dementia, 46.5% for MCI, 9.5% for non-AD, and 6.1% for CU. Among Aβ+ participants with AD dementia and MCI, lower age, MMSE score, and AD-signature cortical thickness showed the strongest associations with tau PET positivity. In non-AD and CU participants, presence of Aβ was the strongest predictor of a positive tau PET scan.
CONCLUSION: We identified several demographic, clinical, and neurobiological factors that are important to explain the variance in tau PET retention observed across the AD pathological continuum, non-AD neurodegenerative disorders, and cognitively unimpaired persons.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
European journal of nuclear medicine and molecular imaging - 48(2021), 7 vom: 04. Juli, Seite 2245-2258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ossenkoppele, Rik [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aβ |
|---|
| Anmerkungen: |
Date Completed 25.06.2021 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00259-020-05099-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31782404X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31782404X | ||
| 003 | DE-627 | ||
| 005 | 20240210232320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-020-05099-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM31782404X | ||
| 035 | |a (NLM)33215319 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ossenkoppele, Rik |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of demographic, clinical, genetic, and imaging variables on tau PET status |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.06.2021 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: A substantial proportion of amyloid-β (Aβ)+ patients with clinically diagnosed Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI) are tau PET-negative, while some clinically diagnosed non-AD neurodegenerative disorder (non-AD) patients or cognitively unimpaired (CU) subjects are tau PET-positive. We investigated which demographic, clinical, genetic, and imaging variables contributed to tau PET status | ||
| 520 | |a METHODS: We included 2338 participants (430 Aβ+ AD dementia, 381 Aβ+ MCI, 370 non-AD, and 1157 CU) who underwent [18F]flortaucipir (n = 1944) or [18F]RO948 (n = 719) PET. Tau PET positivity was determined in the entorhinal cortex, temporal meta-ROI, and Braak V-VI regions using previously established cutoffs. We performed bivariate binary logistic regression models with tau PET status (positive/negative) as dependent variable and age, sex, APOEε4, Aβ status (only in CU and non-AD analyses), MMSE, global white matter hyperintensities (WMH), and AD-signature cortical thickness as predictors. Additionally, we performed multivariable binary logistic regression models to account for all other predictors in the same model | ||
| 520 | |a RESULTS: Tau PET positivity in the temporal meta-ROI was 88.6% for AD dementia, 46.5% for MCI, 9.5% for non-AD, and 6.1% for CU. Among Aβ+ participants with AD dementia and MCI, lower age, MMSE score, and AD-signature cortical thickness showed the strongest associations with tau PET positivity. In non-AD and CU participants, presence of Aβ was the strongest predictor of a positive tau PET scan | ||
| 520 | |a CONCLUSION: We identified several demographic, clinical, and neurobiological factors that are important to explain the variance in tau PET retention observed across the AD pathological continuum, non-AD neurodegenerative disorders, and cognitively unimpaired persons | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Aβ | |
| 650 | 4 | |a Dementia | |
| 650 | 4 | |a MCI | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a Tau | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 700 | 1 | |a Leuzy, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Sudre, Carole H |e verfasserin |4 aut | |
| 700 | 1 | |a Strandberg, Olof |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Ruben |e verfasserin |4 aut | |
| 700 | 1 | |a Palmqvist, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Mattsson-Carlgren, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Olsson, Tomas |e verfasserin |4 aut | |
| 700 | 1 | |a Jögi, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Stormrud, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, Young Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jae Yong |e verfasserin |4 aut | |
| 700 | 0 | |a Alzheimer’s Disease Neuroimaging Initiative |e verfasserin |4 aut | |
| 700 | 0 | |a PREVENT-AD research group |e verfasserin |4 aut | |
| 700 | 1 | |a Boxer, Adam L |e verfasserin |4 aut | |
| 700 | 1 | |a Gorno-Tempini, Maria L |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Bruce L |e verfasserin |4 aut | |
| 700 | 1 | |a Soleimani-Meigooni, David |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccarino, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a La Joie, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Borroni, Edilio |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Pontecorvo, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Devous, Michael D |c Sr |e verfasserin |4 aut | |
| 700 | 1 | |a Villeneuve, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Lyoo, Chul Hyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Rabinovici, Gil D |e verfasserin |4 aut | |
| 700 | 1 | |a Hansson, Oskar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d 2002 |g 48(2021), 7 vom: 04. Juli, Seite 2245-2258 |w (DE-627)NLM116957360 |x 1619-7089 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2021 |g number:7 |g day:04 |g month:07 |g pages:2245-2258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00259-020-05099-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2021 |e 7 |b 04 |c 07 |h 2245-2258 | ||